<DOC>
	<DOC>NCT01043367</DOC>
	<brief_summary>The purpose of the study is to assess the efficacy of DEPREXIL administration in combination with relaxation psychotherapy in the treatment of patients with signs and symptoms of depression. The duration of this double-blind placebo controlled phase 3 clinical trial will be 24 weeks. The estimated number of persons to be recruited and randomized for the study is 200.</brief_summary>
	<brief_title>Deprexil in Subjects With Signs and Symptoms of Depression</brief_title>
	<detailed_description />
	<mesh_term>Depression</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Signs and Symptoms</mesh_term>
	<criteria>Mild or moderate symptoms and signs of depression for more than 3 months and less than 3 years of duration. Signed informed consent Severe symptoms and signs of depression or Suicide proneness. Pregnancy or breastfeeding Receiving other experimental drug Use of antidepressive medication within 15 days</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>59 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>Depression</keyword>
	<keyword>Dietary supplement</keyword>
	<keyword>Deprexil</keyword>
</DOC>